Patents by Inventor Reyhaan Ali Chaudhri

Reyhaan Ali Chaudhri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
    Patent number: 11026996
    Abstract: This invention provides a fusion protein, the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in: (a) an extracellular domain of a human Notch1 receptor protein, followed by (b) an Fc portion of an antibody, wherein the extracellular domain of the human Notch1 receptor protein (i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and (ii) extends to and includes the C-terminal amino acid of EGF-like repeat 18 or 20. Also provided is a composition comprising the any of the fusion proteins of this invention and a pharmaceutically acceptable carrier, a method of treating a subject suffering from age-related macular degeneration (AMD), diabetic retinopathy, or cancer which comprises administering to the subject any of the compositions of this invention in an amount effective to treat the subject's cancer.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: June 8, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jan Kitajewski, Reyhaan Ali Chaudhri
  • HUMAN NOTCH1 BASED FUSION PROTEINS AS DECOY INHIBITORS OF JAGGED-NOTCH SIGNALING AND DLL-NOTCH SIGNALING
    Publication number: 20190183975
    Abstract: This invention provides a fusion protein, the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in: (a) an extracellular domain of a human Notch1 receptor protein, followed by (b) an Fc portion of an antibody, wherein the extracellular domain of the human Notch1 receptor protein (i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and (ii) extends to and includes the C-terminal amino acid of EGF-like repeat 18 or 20. Also provided is a composition comprising the any of the fusion proteins of this invention and a pharmaceutically acceptable carrier, a method of treating a subject suffering from age-related macular degeneration (AMD), diabetic retinopathy, or cancer which comprises administering to the subject any of the compositions of this invention in an amount effective to treat the subject's cancer.
    Type: Application
    Filed: May 25, 2017
    Publication date: June 20, 2019
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Jan Kitajewski, Reyhaan Ali Chaudhri